Seven Fleet Capital Management LP purchased a new position in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH – Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 14,651 shares of the company’s stock, valued at approximately $604,000.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Fairmount Funds Management LLC increased its stake in Dianthus Therapeutics by 22.2% during the 3rd quarter. Fairmount Funds Management LLC now owns 3,307,191 shares of the company’s stock worth $130,138,000 after buying an additional 600,000 shares in the last quarter. Vestal Point Capital LP raised its holdings in shares of Dianthus Therapeutics by 88.2% during the second quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company’s stock valued at $59,616,000 after acquiring an additional 1,499,931 shares during the last quarter. Wellington Management Group LLP lifted its position in shares of Dianthus Therapeutics by 3,366.9% in the third quarter. Wellington Management Group LLP now owns 2,577,662 shares of the company’s stock valued at $101,431,000 after acquiring an additional 2,503,311 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Dianthus Therapeutics by 24.7% in the fourth quarter. Vanguard Group Inc. now owns 2,048,452 shares of the company’s stock valued at $84,417,000 after acquiring an additional 406,254 shares in the last quarter. Finally, TCG Crossover Management LLC boosted its stake in shares of Dianthus Therapeutics by 11.7% in the third quarter. TCG Crossover Management LLC now owns 1,676,624 shares of the company’s stock worth $65,975,000 after acquiring an additional 175,000 shares during the last quarter. 47.53% of the stock is owned by hedge funds and other institutional investors.
Insider Buying and Selling at Dianthus Therapeutics
In other Dianthus Therapeutics news, EVP Simrat Randhawa sold 26,530 shares of the company’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $90.62, for a total value of $2,404,148.60. Following the completion of the sale, the executive vice president directly owned 4,000 shares in the company, valued at $362,480. This represents a 86.90% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Ryan Savitz sold 8,224 shares of the firm’s stock in a transaction on Thursday, April 9th. The stock was sold at an average price of $89.84, for a total value of $738,844.16. Following the completion of the sale, the executive vice president directly owned 8,224 shares of the company’s stock, valued at $738,844.16. This trade represents a 50.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 179,121 shares of company stock worth $15,059,454 in the last three months. 3.02% of the stock is owned by corporate insiders.
Wall Street Analyst Weigh In
View Our Latest Analysis on DNTH
Dianthus Therapeutics Price Performance
DNTH stock opened at $82.49 on Friday. The business has a 50 day simple moving average of $86.74 and a 200-day simple moving average of $66.27. The firm has a market capitalization of $4.51 billion, a PE ratio of -19.97 and a beta of 1.18. Dianthus Therapeutics, Inc. has a 1 year low of $16.64 and a 1 year high of $96.50.
Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($0.85) EPS for the quarter, beating the consensus estimate of ($1.07) by $0.22. Dianthus Therapeutics had a negative return on equity of 27.30% and a negative net margin of 12,998.50%.The firm had revenue of $0.46 million during the quarter, compared to analysts’ expectations of $0.40 million. On average, equities research analysts expect that Dianthus Therapeutics, Inc. will post -3.82 EPS for the current year.
Dianthus Therapeutics Profile
Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.
Featured Stories
- Five stocks we like better than Dianthus Therapeutics
- Credo Technologies Accelerates AI—Its Stock Price Will Follow
- Qualcomm Goes All-In: The $10B Bet to Crush NVIDIA
- Jabil Just Gave Investors a Stronger Reason to Buy the Dip
- CarMax In Reverse? Why You Should Buy Now Before the Big Catalysts Emerge
Want to see what other hedge funds are holding DNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dianthus Therapeutics, Inc. (NASDAQ:DNTH – Free Report).
Receive News & Ratings for Dianthus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dianthus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
